Patent ID: 8912174

Claim:
A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising an aqueous suspension comprising: (a) about 0.05% by weight of suspended solid steroidal anti-inflammatory particles, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable salt, ester, enol ether, enol ester, acid, or base thereof, said suspended solid steroidal anti-inflammatory having the following particle size distribution profile: i. about 10% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.4 microns; ii. about 25% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.8 microns; iii. about 50% of the solid steroidal anti-inflammatory particles have a particle size of less than 1.5 microns; iv. about 75% of the solid steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and v. about 90% of the solid steroidal anti-inflammatory particles have a particle size of less than 5.3 microns; and (b) an antifungal agent; wherein the formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the fluticasone originally present in the formulation still remains in the formulation.